These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32918829)

  • 1. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
    Danjuma MI; Sinha U; Fatima H; Mohamed MFH; Nathoe H
    Eur J Clin Invest; 2020 Nov; 50(11):e13407. PubMed ID: 32918829
    [No Abstract]   [Full Text] [Related]  

  • 2. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
    Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
    J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
    Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
    [No Abstract]   [Full Text] [Related]  

  • 4. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
    Asensio E; Acunzo R; Uribe W; Saad EB; Sáenz LC
    J Interv Card Electrophysiol; 2020 Nov; 59(2):315-320. PubMed ID: 32418181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
    Monzani A; Genoni G; Scopinaro A; Pistis G; Kozel D; Secco GG
    Eur J Clin Invest; 2020 Jun; 50(6):e13258. PubMed ID: 32356580
    [No Abstract]   [Full Text] [Related]  

  • 6. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine and hydroxychloroquine during pregnancy: What do we know?
    Lacroix I; Bénévent J; Damase-Michel C
    Therapie; 2020; 75(4):384-385. PubMed ID: 32418732
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?
    Marmor MF
    Am J Ophthalmol; 2020 May; 213():A3-A4. PubMed ID: 32247518
    [No Abstract]   [Full Text] [Related]  

  • 9. Chloroquine and hydroxychloroquine repositioning in times of COVID-19 pandemics, all that glitters is not gold.
    Paumgartten FJR; Delgado IF; Pitta LDR; Oliveira ACAX
    Cad Saude Publica; 2020; 36(5):e00088520. PubMed ID: 32428074
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 11. The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question.
    Cirino G; Ahluwalia A
    Br J Pharmacol; 2020 Aug; 177(15):3361-3362. PubMed ID: 32602956
    [No Abstract]   [Full Text] [Related]  

  • 12. Concentration-dependent mortality of chloroquine in overdose.
    Watson JA; Tarning J; Hoglund RM; Baud FJ; Megarbane B; Clemessy JL; White NJ
    Elife; 2020 Jul; 9():. PubMed ID: 32639233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19.
    Fassihi SC; Nabar NR; Fassihi R
    Br J Pharmacol; 2020 Nov; 177(21):4997-4998. PubMed ID: 32562278
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.
    Roden DM; Harrington RA; Poppas A; Russo AM
    Heart Rhythm; 2020 Jul; 17(7):e231-e232. PubMed ID: 32302703
    [No Abstract]   [Full Text] [Related]  

  • 15. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
    Kamp TJ; Hamdan MH; January CT
    J Am Heart Assoc; 2020 Jun; 9(12):e016887. PubMed ID: 32463308
    [No Abstract]   [Full Text] [Related]  

  • 16. Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19).
    Gao J; Hu S
    Biosci Trends; 2020 May; 14(2):156-158. PubMed ID: 32281583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and hydroxychloroquine: Is the wonder drug failing?
    Paliani U; Cardona A
    Eur J Intern Med; 2020 Aug; 78():1-3. PubMed ID: 32553587
    [No Abstract]   [Full Text] [Related]  

  • 18. The Use of "Novel Pharmacology" in the Treatment of COVID-19 and Potential Psychiatric Risks.
    Yahya AS; Khawaja S; Chukwuma J
    Prim Care Companion CNS Disord; 2020 May; 22(3):. PubMed ID: 32441496
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
    Gopinathannair R; Merchant FM; Lakkireddy DR; Etheridge SP; Feigofsky S; Han JK; Kabra R; Natale A; Poe S; Saha SA; Russo AM
    J Interv Card Electrophysiol; 2020 Nov; 59(2):329-336. PubMed ID: 32494896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.